Price
27.68
+2.7%52W Range
Market Cap
₹43.81 Cr
Traded: ₹0.07 Cr (0.15%) 0.0x
Free Float: ₹27.60 Cr (0.24% of FF traded)
Volume · 60D trend
23.62 K 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Profit | -- | -- | -- | -- | -767.0% | -- |
| Return | -18.0% | -26.0% | -35.0% | -63.0% | -- | Decelerating |
| ROE | -- | -- | -12.0% | -- | -- | -- |
| Sales | -- | -- | -- | -- | -27.0% | -- |
Quarterly Results
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 57 | 67 | 58 | 50 | 57 | 73 | 89 | 80 | 77 | 102 | 97 |
| Expenses | 56 | 73 | 60 | 52 | 62 | 63 | 80 | 71 | 68 | 91 | 90 |
| Operating Profit | 1 | -6 | -2 | -3 | -5 | 10 | 9 | 9 | 8 | 12 | 7 |
| OPM % | 1.6% | -8.3% | -2.6% | -5.7% | -8.1% | 13.6% | 9.9% | 10.9% | 10.7% | 11.4% | 7.2% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 4 | 3 | 4 | 5 | 4 | 4 | 3 | 4 | 4 | 4 | 3 |
| Depreciation | 4 | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 4 | 4 | 4 |
| Profit Before Tax | -7 | -13 | -10 | -12 | -13 | 2 | 1 | 1 | 1 | 4 | 0 |
| Tax % | 13.2% | 1.1% | 0.0% | -41.1% | 6.2% | 95.7% | 5.8% | -124.2% | -362.1% | 10.2% | -1150.0% |
| Net Profit | -8 | -13 | -10 | -7 | -14 | 0 | 1 | 3 | 3 | 4 | 1 |
| Exceptional Items | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| EPS (Rs) | -4.8 | -8.5 | -6.2 | -4.6 | -8.7 | 0.0 | 0.8 | 1.7 | 1.7 | 2.2 | 0.3 |
| Sales Growth (YoY) | -0.2% | -7.5% | -34.2% | -38.0% | -25.3% | -28.8% | -8.9% | -- | -- | -- | -- |
| Sales Growth (QoQ) | -- | 15.5% | 16.0% | -12.3% | -21.9% | -18.0% | 11.3% | 3.9% | -24.5% | 5.2% | -- |
| OP Growth (YoY) | 119.7% | -156.8% | -117.6% | -132.6% | -156.4% | -15.3% | 25.6% | -- | -- | -- | -- |
| OP Growth (QoQ) | 116.2% | -264.9% | 45.8% | 38.5% | -146.7% | 12.9% | 0.8% | 6.2% | -29.9% | 67.5% | -- |
| Profit Growth (YoY) | 44.6% | -22466.7% | -862.8% | -373.2% | -614.9% | -98.3% | 158.0% | -- | -- | -- | -- |
| EPS Growth (YoY) | -- | -21300.0% | -858.5% | -372.9% | -616.0% | -98.2% | 156.3% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -- | -36.3% | -34.0% | 46.8% | -21900.0% | -95.1% | -51.8% | 0.6% | -24.2% | 596.9% | -- |
| OP Margin | -- | -9.0% | -3.5% | -6.0% | -7.0% | 13.7% | 10.1% | 11.3% | 10.4% | 11.8% | 7.2% |
| Net Margin | -- | -19.4% | -17.2% | -14.0% | -24.6% | 0.0% | 1.1% | 3.8% | 3.9% | 3.9% | 0.0% |
| Material Cost % | 58.0% | 70.0% | 64.0% | 67.0% | 69.0% | 49.0% | 57.0% | 51.0% | 53.0% | 57.0% | 71.0% |
| Employee Cost % | 16.0% | 13.0% | 14.0% | 15.0% | 16.0% | 14.0% | 12.0% | 13.0% | 12.0% | 11.0% | 9.0% |
| P/S | 0.19 | 0.19 | 0.20 | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 0.43 | 0.42 | 0.38 | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Newspaper publication for declaration of Un-audited Financial Results (Standalone & Consolidated) for the quarter ended 30th June, 2026
Appointment of Secretarial Auditor of the Company for term of 5 years from F.Y. 2026-27 to 2030-31 subject to approval of shareholders in ensuing 53rd AGM of the Company
Appointment of Statutory Auditor for the period of 5 years subject to approval of sharehoders at ensuing 53rd Annual General meeting.
Declaration of Un-audited Financial results (Standalone & Consolidated) for the quarter ended 30th June, 2026
Outcome of Board meeting held on 12th August, 2026 interalia for approval of Un-Audited Financial results (Standalone & Consolidated) for the quarter ended 30th June, 2026
Intimation pursuant to Regulation 30 read with Schedule III of SEBI (LODR), Regulations, 2015 regarding resiagntion tendered by Ragini Chokshi & Co., Secretarial Auditor of the Company ....
Mangalam Drugs & Organics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 ,inter alia, to consider and approve Prior Intimation ....
Intimation regarding certificate received from Registrar and Transfer agent under Regukation 74(5) of SEBI (DP) Regulations, 2018
Intimation of closure of trading Window for the period ended 30th June, 2026
Disclosure of Voting Results and Scrutinizers Report for Postal ballot pursuant to Regulation 44 (3) of SEBI LODR, 2025 for re-appointment of Mr. Praveen Saxena as an Independent Director ....
Disclosure of Voting Results and Scrutinizers Report for Postal ballot pursuant to Regulation 44 (3) of SEBI LODR, 2025 for re-appointment of Mr. Praveen Saxena as an Independent Director ....
Annual Secretarial Compliance Report to be filed for the financial year ended March 31, 2026 as per Regulation 24A of SEBI LODR, 2025.
Submission of Annual Secretarial Compliance Report for the period ended 31st March, 2026
Disclosure under Regulation 30 of LODR 2015 for newspaper publication regarding the dispatch of Postal Ballot/ E- Voting seeking shareholders approval.
Disclosure of notice of postal ballot /E- Voting seeking shareholders approval pursuant to Regulation 30 of SEBI LODR, 2015 . for reappointment of Shri Praveen Saxena as an Independent ....
Newspaper Publication for declaration of Annual Financial Results (Consolidated and Standalone) for the quarter and financial year ended March 31, 2026.
Outcome of Board Meeting held on 14th May 2026 for declaration of Audited Financial Results (Standalone & Consolidated) of the Company for the period ended 31st, March, 2026
Approval of Financial Results (Standalone & Consolidated) for the quarter and year ended 31st March, 2026
Mangalam Drugs & Organics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/05/2026 ,inter alia, to consider and approve Intimation of Board ....
The Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on April 29, 2026 for Aditya Ramniwas Dhoot
The Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on April 29, 2026 for Shree Rasbihari ....
The Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on April 29, 2026 for Shree Kishoriju ....
Additional details required for Corporate Announcement filed under Regulation 30 of SEBI(LODR) Regulations, 2015 read with Schedule III Part A Para A of 7 & 7C for submission of resignation ....
Additional details required for Corporate Announcement under Regulation 30 of SEBI(LODR) Regulations, 2015 read with schedule III, Part A, Para A of 7 & 7(C) for submission of resignation ....
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on April 10, 2026 for Shree Kishoriju Trading ....
Submission of Compliance Certificate received from RTA under Regulation 74(5) of SEBI(DP) Regulations, 2018
Resignation tendered by CS Anuradha Pandey accepted by the Board, approval for the appointment of New Company Secretary nominated by NRC, Ms. Shweta Patel.
Outcome of Board meeting to accept the resignation tendered by Ms. Anuradha Pandey as Company Secretary & Compliance Officer(KMP) & Appointment of Ms. Shweta Patel as Company Secretary ....
Intimation of closure of Trading Window for the Financial Year ended 31st March, 2026
Mangalam Drugs & Organics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/03/2026 ,inter alia, to consider and approve Board Meeting intimation ....
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on March 18, 2026 for Shree Rasbihari Trading ....
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on March 18, 2026 for Aditya Ramniwas Dhoot
Outcome of Board meeting dated 6th February, 2026 for change in management
Outcome of Board meeting
Mangalam Drugs & Organics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/02/2026 ,inter alia, to consider and approve Board meeting to ....
Disclosure of change in credit rating as received from CRISIL
Disclosure Pursuant to Regulation 30, Schedule III, Part A, Para 7(B) of SEBI(LODR) Regulations, 2015 for resignation of Mr. Rukmesh P. Dhandhania -Independent Director of the Company.
Pursuant to Regulation 30, Schedule III, Part A, Para A(7B) Intimation of resignation of Shri Rukmesh P. Dhandhania- Independent Director of the Company w.e.f. 16th January, 2026
Outcome of Board meeting held on 15th January, 2026 for declaration of Un-Audited Financial results of the Company for the quarter ended 31st December, 2025
Intimation of Newspaper publication for declaration of Un-Audited Financial Results for the quarter ended 31st December, 2025
Acceptance of resignation tendered by Ajay Avinash Samant- Chief Financial Officer of the Company effective from 31st January, 2026
Outcome of Board Meeting held on 15th January, 2026 inter alia to approve un-audited Financial Results for the quarter ended 31st December, 2025
Certificate under Regulation 74(5) of SEBI(Depositories and Participants) Regulations, 2018
Mangalam Drugs & Organics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 15/01/2026 ,inter alia, to consider and approve Intimation of Board ....
Clarification for the query raised by Surveillance Department of BSE Limited dated 5th January,2026 regarding Movement in price of the Company.
The Exchange has sought clarification from Mangalam Drugs & Organics Ltd on January 5, 2026 with reference to significant movement in price, in order to ensure that investors have latest ....
Intimation of closure of Trading Window from January 1, 2026 till the expiry of Forty-eight (48) hours after the declaration of Un- Audited Financial Results for the period ended 31st December, 2025.
Explanation to the intimation filed on 29th March, 2025 regarding reasoning for the resignation of Chief Financial Officer of the Company.
Intimation of repeat international order clients amounting to approx 15 Crores.
Intimation of outcome of Board meeting held on 20th November, 2025 at 12:00 p.m. to approve standalone and consolidated un-audited financial results of the Company for the quarter ended ....
Annual Reports
14Credit Ratings
6